Introduction
Immunotherapy has made quantum leaps in recent decades, regardless of humoral or cellular immunotherapy. As regards to the former one, monoclonal antibodies are gradually receiving widespread clinical application, with some examples being bevacizumab, rituximab, trastuzumab, and checkpoint inhibitors, including programmed death-1 (PD-1)/pro-grammed death-ligand1 (PD-L1) blockade (pembrolizumab), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockade (Ipilimumab) (Gross et al., 1989; Al-Hilli et al., 2019; Amrane et al., 2019; Henon et al., 2019; Sharma et al., 2019; Soumerai et al., 2019; Tian et al., 2019) . For the latter one, cellular immunotherapy has witnessed the development and testing of T-cell receptor (TCR)-redirected cell therapy and TCR autologous tumor-infiltrating lymphocytes (TILs) (Takayama et al., 2000; Goff et al., 2016) . Nevertheless, both humoral and cellular immunotherapies have their own shortcomings. The effect of monoclonal an-tibodies highly depends on the genetic characteristics (tumor cells whose genome contain deficient mismatch repair and microsatellite instability are sensitive), specific antigens of cancer cells, and the surrounding immune microenvironment (Yaghoubi et al., 2019) . Moreover, the proportion of patients, who receive long-term benefits, is still limited (Schadendorf et al., 2015) . The T-cell-mediated cytotoxicity greatly relies on the human leukocyte antigen (HLA), which is produced by major histocompatibility complex (MHC) (Ti et al., 2018) . To make matters complicated, the difficult isolation of TILs from the cancerous tissue poses another obstacle for clinical progression . Therefore, a new immunotherapy pattern is urgently needed.
Around 25 years ago, scientists have combined variable regions of an antibody with the constant regions of the TCR to create the chimeric antigen receptor (CAR) T cells (CAR-T), which is an all-in-one approach where a T cell can be engineered to possess the antibody's specificity, homing, tissue penetration, and independent cytotoxicity from MHC molecules (Eshhar et al., 1993; Mirzaei et al., 2017) . The primary difference between CAR-T and traditional T cells is that the former one is equipped with a CAR part in addition to the TCR complex ( Figure 1A-D) . The main structure of the CAR includes extracellular, transmembrane, and intracellular domains. The first one is a tumor-antigen-binding domain, which is frequently derived from the variable light (V L ) and variable heavy (V H ) sequences of a monoclonal antibody (scFv) connected by a peptide linker (Muniappan et al., 2000; Sadelain et al., 2003) ( Figure 1B) . The transmembrane portion originates from CD3-Zeta chain (CD3-ζ), CD4, CD8, CD28, ICOS, etc. (Sadelain et al., 2013; Li and Zhao, 2017; Van Schandevyl and Kerre, 2018) . The intracellular domain is initially a CD3ζ intracellular signaling domain capable of activating T cells, and it can be fused with one or more co-stimulatory molecules (Eshhar et al., 1993) . Currently, four generations of CAR-Ts exist, and the distinction between each generation is generally the constitution of the intracellular domain. The first-generation CAR (Figure 1B) exclusively consists of CD3-ζ or Fc receptor γ (FcRγ) in an intracellular motif, which results in temporary T-cell activation (Brocker and Karjalainen, 1995) . The second ( Figure 1C ) and third generations ( Figure 1D ) of CARs were built upon the foundation of the first generation by adding one (second generation) or more co-stimulatory molecules (third generation), such as CD28, 4-1BB, or OX40. These signaling domains induce expansion of T cells, increase cytokine secretion, and enhance their anti-tumor immunity (Finney et al., 2004) . The fourth-generation CAR-T cells will be elaborated in the following sections (Van Schandevyl and Kerre, 2018) .
Currently, the majority of studies regarding CAR-T are focused on hematological malignancies and have demonstrated excellent progress. Almost half of all CAR-T studies investigated CD19, a surface antigen of various B-cell malignancies (Beatty and O'Hara, 2016) . The second generation of CD19-specific CAR-T cells with a 4-1BB costimulatory domain has achieved complete remission (CR) rates of 90% in patients with chemotherapy-resistant or refractory (r/r) leukemia or lymphoma. About 70% of patients who achieved CR were stable for about half a year; similarly, Figure 1 Basic structures of natural T-cell receptor (TCR) complex and CAR. T-cell receptor (A) consists of variable chains called α, β or δ, γ, depending on the cell types. CD3ζ is its constant portion located trans-and intracellularly. On the other hand, CAR replaces the variable chains of T-cell receptor with variable fragments from heavy and light chains of monoclonal antibodies (scFv). All three generations of CARs have a similar extracellular part: variable fragments from heavy and light chains of monoclonal antibodies. Regarding the TM part, the first-generation TM portion generally originates from the natural TCR of CD3ζ, CD4, or CD8 (B); the second-(C) and the third-(D) generation CARs utilize either CD3ζ or CD28. As for the intracellular part, the first generation only possesses CD3ζ to enable the T-cell activation (B), whereas the second (C) and the third (D) generations possess one and two co-stimulatory domains for strengthening the function of T cells, respectively. CAR, chimeric antigen receptor; scFv, mouse monoclonal antibody; TM, transmembrane part; V L , variable light chain; V H , variable heavy chain.
other trials have shown that CD19-CD28 CAR-T cells attained an 88% complete response rate in the adult group (Porter et al., 2011; Grupp et al., 2013; Davila et al., 2014; Maude et al., 2014; Brudno et al., 2016) . Unlike hematological research, the CAR-T cell therapy in solid tumors takes place on a new battleground. For several years, various preclinical trials (Table 1) and clinical trials (Tables 2 and 3 ) are devoted to the research of typical tumorassociated antigens such as carcinoembryonic antigen (CEA), disialoganglioside (GD2), mesothelin (MSLN), human epidermal growth factor receptor-2 (HER2), epidermal growth factor receptor (EGFR), and many other tumor antigens (FAP, IL13Rα2, MUC1, PSCA, PSMA) (Townsend et al., 2018) . Generally, most of them are non-specifically expressed on the surface of different cancer cells such as breast cancer, gastrointestinal cancer, pancreatic cancer, mesothelioma, and ovarian cancer, whereas some are organ-specific (i.e., PSCA and PSMA are only expressed in prostate cancer) (Martinez and Moon, 2019) . So far, a few side effects of CAR-T cell infusion were recorded: fever, abnormal liver enzyme elevation, pain, and other Grade 1-2 toxicities (abnormal blood routine results) (Neelapu et al., 2018; , whereas a minority of participants suffered from Grade 3-4 adverse events (i.e., leukopenia, hyperbilirubinemia, congestive rashes, systemic subcutaneous hemorrhages, serum cytokine release) (Neelapu et al., 2018; Wang et al., 2018) . Hence, there is much room for improvement for the response to treatment. The cases, where the clinical responses were recorded, generally reported no considerable improvements. Unfortunately, most of the patients experienced deteriorating conditions or death due to the solid malignancies during treatment or in the process of follow-up. A number of factors, such as the self-origin of tumor antigens, antigen loss, the downregulation of HLA expression, resistance to CTLs, and environmental suppression, are known to hamper the advancements in the application of CAR-T cells (Sadelain et al., 2003) . The purpose of this review is to outline the main issues and solutions of CAR-T cells for the treatment of solid tumors.
Main obstacles of CAR-T cell treatment for solid tumors: solid tumor microenvironment (TME)

Poor tumor locating ability
One of the main reasons for the achievement of promising results by CAR-T cells in hematological malignancies is that the infused cells can directly target the tumor cells located in the bloodstream, thereby negating the need for the CAR-T cells to seek for targets. In contrast, to attack the solid tumor cells, T cells have to first locate the tumor cells and reach the specific tumor sites via homing to the nearby lymph nodes or passing through the blood vessels. Even in the event of reaching the surface of the solid tumor, the dense extracellular matrix would restrict the penetration and infiltration of these CAR-Ts, hence preventing CAR-T cells from gaining access to the target (Mikucki et al., 2015) ( Figure  2A ). The regional or intratumoral application of adoptive T cells can not only exert an effective and persistent anti-tumor function in the tumor site, circumventing dense extracellular matrix, but also reduce the risk of systemic off-target toxicity (Parente-Pereira et al., 2011; Tchou et al., 2017) . Studies have indicated that chemokines play a pivotal role in the restriction of homing abilities (Mullins et al., 2004; Harlin et al., 2009; Mlecnik et al., 2010; Martinet et al., 2012; Evans et al., 2015) . Solid tumors can produce and secrete chemokines such as C-C chemokine ligand 2 (CCL2), but their corresponding receptors, chemokine (C-C motif) receptor (CCR) 2b, and CCR4, are sparsely distributed on the membrane of adoptive T cells, thereby causing the homing ability onto the tumor site to be disabled (Moon et al., 2011) ( Figure 2B ). Conversely, it is known that the major chemokine receptor is C-X-C motif chemokine ligand 3 (CXCL3), which mediates the migration of effector T cells to the tumor sites. It binds to the tumor-derived CXCL9 and CXCL10 (Mikucki et al., 2015) . CCL5, which is secreted by tumor cells, can bind with its CCR5 receptor on T cells, thus indicating good T-cell intralesional infiltration and offer promising prognosis in the patients with melanoma and colorectal cancer (Sapoznik et al., 2012; Bedognetti et al., 2013) . However, only a small amount of these molecules is expressed by tumor cells (Gobert et al., 2009 ) ( Figure 2C ). Some tumors, including prostate cancer, secrete chemokines such as CXCL2, CXCL5, CXCL12, CCL22, and CCL28, which attract myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs), the two major immunosuppressive cells neutralizing the cytotoxicity of effector T cells in solid tumors (Gobert et al., 2009; Facciabene et al., 2011; Hillerdal and Essand, 2015) ( Figure 2D ). These chemokines significantly thwart the homing ability of effector T cells. In some solid tumors, the expression of lymphocyte integrin decreased, including lymphocyte function-associated antigen (LFA-1) and VLA-4. Weak binding of effector T cells to intracellular adhesion molecules 1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) adversely affects the T-cell migration .
Regulatory T cells and cytokines
Treg is a subset of the CD4 + T cell family, accounting for 5% of the entire T-cell population in humans (Frydrychowicz et al., 2017) (Figure 3 ). a) AFP, alpha fetoprotein; ASGR-1, Asialoglycoprotein receptor 1; CEA, carcinoembryonic antigen gene family; EpCAM, epithelial cell adhesion molecule; FAP, fibroblast activation protein; FR-α, folate receptor-alpha; FITC, fluorescein isothiocyanate; GD2, disialoganglioside; GPC, glycoprotein precursor; GITR, glucocorticoid-induced TNFR-related protein; Her-2, human epidermal growth factor receptor 2; IL13Rα2, interleukin 13 receptor α2; MSLN, mesothelin; MUC, mucin; NKG2D, natural killer group 2 member D; NSG, NOD/SCID/γ-chain-/-mice; PSMA, prostate-specific membrane antigen; TAG-2, tumor-associated glycoprotein 72; VEGFR-2, vascular endothelial growth factor receptor 2.
Figure 2
Factors adversely affecting the locating and homing abilities of CAR-T cells in the tumor microenvironment. To battle the solid tumors, CAR-T cells must overcome a few obstacles. The main mechanism is homing to proximal lymph nodes or extravasation through blood vessels. However, ligandreceptor mismatch makes this process much more difficult. Despite arriving at their destination, the dense extracellular matrix poses another hurdle that prevents the CAR-T cells from executing their cytotoxicity (A). As regards to ligand-receptor mismatch, CCL2 is secreted by the tumor cells but its corresponding receptor is absent in T cells, further resulting in homing disability (B). On the contrary, CXCR3 and CCR5, which are expressed on T cells, can bind with CXCL9, CXCL10, and CCL5, which are produced by the tumor cells. However, these tumor-derived molecules are only present in small amounts in the tumor microenvironment (C). The homing of T cells will be more difficult when chemokines, such as CXCL2, CXCL5, CXCL12, CCL22, and CCL28, from tumors introduce two immunosuppressive cells, MDSCs and Tregs, into the solid tumor milieu (D). CCL2, C-C chemokine ligand 2; CCR5, chemokine (C-C motif) receptor; CXCL, C-X-C motif chemokine ligand; CXCR, C-X-C motif chemokine receptor; MDSC, myeloid-derived suppressor cell; T, CAR-T cell; Treg, regulatory T cell. a) *, T4 is a kind of autologous T cells genetically equipped with a retroviral vector and it co-expresses two chimeric receptors: T1E28z, consisting of multiple ErbB dimers; 4αβ, a chimeric cytokine receptor that can stimulate expansion and enrichment of T4 (+) T-cells ex vivo. CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; EGFRvIII, epidermal growth factor receptor variant III; EPCAM, epithelial cell adhesion molecule; EphA2, EPH receptor A2; FAP, fibroblast activation protein alpha; GD2, disialoganglioside; GPC 3, glypican 3; HCC, hepatoellular carcinoma; HER2, human epidermal growth factor receptor-2; IL13Rα2, interleukin 13 receptor-α2; L1CAM, L1 cell adhesion molecule; MLSN, mesothelin; MUC1, mucin 1, cell surface associated; MUC16ecto, mucin 16 ecto; NY-ESO-1, cancer/testis antigen 1; PDAC, pancreatic ductal adenocarcinoma; PSCA, prostate stem cell antigen; PSMA, prostate-specific membrane antigen; ROR1, receptor tyrosine kinase like orphan receptor 1. No clinical response (median overall survival: cohort 1: 9.5 months (range: 3-33 months); cohort 2: 2 months; cohort 3: 12.5 months (6-24 months). Side effects: 2 of 3 patients in cohort 1 developed short-term grade 3-4 liver enzyme elevation. The same number of patients in cohort 2 suffered the same condition whereas no dose-related toxicities or higher than grade 1 liver toxicity were observed. 8.5 month PR (CART-EGFR therapy) 4.5 month-lasting PR (CART-CD133 therapy) Side effect: CART-EGFR therapy: mild chills, fever, fatigue, vomiting and muscle soreness, and a 9-day duration of delayed lower fever, accompanied by escalation of IL-6 and C reactive protein (CRP), acute increase of glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase, and grade 2 lichen striatus-like skin pathological changes. CART-CD133 cells: grade 3 systemic subcutaneous hemorrhages and congestive rashes together with serum cytokine release, which needed emergent medical intervention including intravenous methylprednisolone. Whiteside, 2014) . Treg is a heterogeneous subpopulation, and at least two Treg subsets, naturally occurring Treg cells (nTregs) and inducible or adaptive Tregs (iTregs), have been discovered in humans. They differ by possessing dissimilar types of surface antigens (Miyara and Sakaguchi, 2011) . In the solid TME, nTreg triggers immunosuppression by cellcell contact in the pathways, which are predominated by granzyme B/perforin or Fas/FasL (Jonuleit et al., 2001; Grossman et al., 2004; Strauss et al., 2009 ). In addition, this pathway is highly dependent on IL-2, but they inversely a) CAIX, carboxy-anhydrase IX; CEA, carcinoembryonic antigen; CR, complete response; EGFR, epidermal growth factor receptor; FR-α, folate receptor alpha; GD2, disialoganglioside; GPC 3, glypican 3; HCC, hepatocellular carcinoma; Her-2, Human Epidermal growth factor Receptor-2; IL13Rα2, interleukin 13 receptor-α2; L1CAM, L1 cell adhesion molecule; MLSN, mesothelin; PR, partial response; PSCA, prostate stem cell antigen; SD, stable disease; VEGFR-II, Vascular endothelial growth factor receptor II; PSMA, prostate-specific membrane antigen.
repress the effector T-cell function by inhibiting their expression and production of IL-2 (Shevach, 2002) . nTreg can persist and exhibit stable functioning in the periphery (Azimi et al., 2016) . It can be further differentiated into Th1-Treg, Th2-Treg, Th17-Treg, Fat-Treg, and Tfr-Treg. In contrast to nTreg, iTreg is derived from CD4 + CD25 mature T cells in the peripheral tissue following the stimulation of antigens from the antigen-presenting cells (typically immature dendritic cells (DC)) (Steinbrink et al., 1997; Jonuleit et al., 2000; Jonuleit and Schmitt, 2003; Shevach, 2006; Nedoszytko et al., 2017) . The functional characteristics of iTreg include independence from cell-cell contact and cytokinerelated immunosuppression by IL-10 and transforming growth factor-β (TGF-β) (Jonuleit and Schmitt, 2003) . TGFβ is capable of dampening the function of effector T cells and inducing the switching of effector T cells into the regulatory phenotype (Chen et al., 2005; Liu et al., 2007) . iTreg can be further classified into two types: Foxp3 + and Foxp3 - (Chen et al., 2003; Sakaguchi et al., 2008; Nedoszytko et al., 2017) . According to the measurements from one bench study, in the tumor environment, Treg accounts for approximately 15% of the total CD4 + cells and approximately 20% of TIL and lymphocytes in nodes (Liyanage et al., 2002) . Tumor cells also play an important role in Treg's immunosuppression.
Researchers have found that cancer cells can secret TGF-β and chemokine CCL22 to trigger Treg differentiation and recruit peripheral Tregs to counteract the anti-tumor function of T cells (Curiel et al., 2004; Chen et al., 2005) . Owing to the difficulty of eliminating Tregs in the TME (Byrne et al., 2011) and the high production of TGF-β from Tregs, it is crucial to prevent TGF-β-mediated immunosuppression. Thus, one study designed a dominant-negative TGF-β receptor II on CAR-T cells, thus assuring better proliferation, infiltration, anti-tumor immunity, and persistence in the mouse prostate cancer models (Kloss et al., 2018) .
Myeloid-derived suppressor cell (MDSC)
MDSCs include various populations of cells derived from the bone marrow, which includes immature myeloid progenitors for neutrophils, monocytes, and DC (Yang et al., 2004; Ornstein et al., 2018) . According to their surface molecules, MDSC can be divided into two subtypes: CD11b + Gr1 hi , which represents the immature neutrophil phenotype and is designated polymorphonuclear MDSC (PMN-MDSC), and CD11b + Gr1 low , which comprises the cells with a monocyte-like phenotype and is termed monocytic MDSC (m-MDSC) (Movahedi et al., 2008; Sawanobori et al., 2008; Marigo et al., 2010; Ben-Meir et al., 2018) ( Figure 4) . The immunosuppressive nature of MDSC induces the downregulation of the function of T, B, natural killing (NK), and DC in cancerous or cancer-free peripheral microenvironments Baniyash, 2016; Gabrilovich, 2017; Meirow and Baniyash, 2017) . MDSCs mainly attack T cells (Gabrilovich, 2017) , and different subpopulations of MDSCs are known to suppress the mature T cells in the periphery. Instead of killing cells via contact, iTreg generally eliminates the T cells via IL-10 and TGF-β suppression. In contrast to nTreg, iTreg can be further differentiated into Foxp3 -. Tumor cells can also stimulate Treg differentiation, thereby adversely affecting the anti-tumor function of T cells. iTreg, inducible or adaptive Treg cells; nTreg, naturally occurring Treg cells; MHC, major histocompatibility complex. effect of T cells via different mechanisms (Gabrilovich, 2017) . It was found that PMN-MDSC neutralizes the immune response via an antigen-specific pattern, whereas the m-MDSC convicted this crime via both antigen or non-antigen-specific patterns (Gabrilovich et al., 2012) (Figure 4A -D). In the antigen-specific immunosuppressive pathway of MDSC, reactive oxygen species (ROS) is a key element including hydrogen peroxide, superoxide anion, and peroxynitrite (PNT) (Gabrilovich, 2017) . Superoxide reacts with nitric oxide (NO), a chemical produced by the NO synthase 2 (nos2) gene in MDSC, and generates PNT ( Figure 4A ), a molecule that can directly weaken the function of T cells by nitrating TCR ( Figure 4B ) and impairs their alertness to the homogenous antigen-MHC complexes (Nagaraj et al., 2007) ( Figure 4C ). In addition, PNT is also capable of preventing the T-cell migration via the nitration of T-cell specific chemokines (Lu et al., 2011; Molon et al., 2011) . To survive this oxidative environment, CAR-T cells have been genetically modified to produce an anti-oxidant intracellular enzyme catalase (CAR-CAT), which have resulted in promising antitumor capabilities (Ligtenberg et al., 2016) . Additionally, PMN-MDSC can secrete arginase and indoleamine, both of which can decompose amino acids, which are necessary for T-cell growth and activation (Bronte et al., 2003; Yu et al., 2013) . This is proven by published results in which the ex-haustion of PMN-MDSC protects the efficacy of CAR-T cells (Burga et al., 2015) . Cytokines that induce IL-6 and IL-10 also play a key role in mediating MDSC's immunosuppressive function. To promote a pro-TME, MDSC produces the increasing amounts of IL-10, thereby leading to the downregulation of IL-6, IL-12, and tumor necrosis factor-α (TNF-α) and upregulation of NO from macrophages (Beury et al., 2014) ( Figure 4E ). Macrophages can stimulate the IL-10 production of MDSC (Gabrilovich et al., 2012) ( Figure 4E ), but extrinsic IL-6 (macrophage-secreting or other source) has no direct effect on IL-10 (Beury et al., 2014) . Additionally, tumor cells and MDSC can stimulate IL-6 production from one another, thus contributing to the whole immunosuppressive environment (Sinha et al., 2007; Bunt et al., 2009; Beury et al., 2014) (Figure 4F ). Among these cytokines, IL-6 stimulates the tumor cell growth, development, and vascularization while reducing tumor cell death (Becker et al., 2005; Santer et al., 2010; Su et al., 2011) . IL-10 supports tumor growth, suppresses T-cell-related cytotoxicity, and prevents tumor-specific helper T type 1 (Th1) responses (Garcia-Hernandez et al., 2002; Kawamura et al., 2002; Yang and Lattime, 2003) (Figure 4G ). Interestingly, MDSC can interfere with the communication between tumors and macrophages as it can suppress the yield of macrophages of IL-6 in the tumor's presence while sti- According to the cell surface biomarkers, MDSC can be categorized into PMN-MDSC and m-MDSC. The former group can negatively affect the potency of T cells by ROS, which can react with NO to produce peroxynitrite (PNT) (A). PNT can nitrate TCR, thereby leading to a weakened combination of TCR and MHC molecules (B). In addition, PNT can disrupt the linkage between MHC and tumor antigens to blunt the alertness of T cells (C). On the contrary, m-MDSC can utilize both antigen-and non-antigen-specific patterns to interfere with the immune capability of T cells (D). The non-antigen-specific pattern mainly includes cytokines such as IL-6, IL-10, IL-12, and TNF-α. Macrophages can stimulate exclusive IL-10 expression in MDSC, whereas IL-10 from MDSC reversely inhibits the expression of IL-6, IL-12, and TNF-α by macrophages, with the exception of increasing NO secretion (E). IL-6 can be generated by MDSC, tumor cells, and macrophages, whereas the tumor cells and MDSC can stimulate each other's yield of IL-6 (F). IL-10 is produced by MDSC and, akin to IL-6, it is also an immunosuppressive molecule that can weaken the T-cell activation (G). MDSC can adversely affect IL-6 production and positively affect the NO production of macrophages in the tumor microenvironment (H). IL-12 is generally secreted by macrophages and can trigger T-cell activation (I). NO is a two-edged sword, possessing both immune activation and depression traits (J). MHC, major histocompatibility complex; M-MDSC, monocytic MDSC; PMN-MDSC, polymorphonuclear MDSC; NO, nitric oxide; ROS, reactive oxygen species; TNF-α, tumor necrosis factor-α. mulating NO production of macrophages in the tumor tissue (Beury et al., 2014) ( Figure 4H ). IL-12 from macrophages promotes the differentiation of naïve helper T cells to Th1 phenotype and activates the function of cytotoxic T cells, natural killer T cells, and conventional NK cells (Vom Berg et al., 2013) (Figure 4I ). TNF-α can trigger DNA damage of tissue cells, inhibit their apoptosis, and enhance tumor cell invasion and metastasis by increasing the production of cytokines, chemokines, and matrix metalloproteases (Balkwill, 2006) . In contrast to the cytokines above, NO possesses both pro-tumor and anti-tumor activities ( Figure 4J ). The former function is executed when NO is produced by MDSC, and the latter function is activated when it is secreted by M1-like macrophages (Hussain et al., 2004; Bronte and Zanovello, 2005) .
Tumor-associated macrophages (TAM)
TAM are present abundantly in the solid TME (Fujimura et al., 2018) , especially in inflammation-mediated and hypoxic tumor sites (Qu et al., 2018; Shrivastava et al., 2019) . Gentles et al. found that a high burden of TAM is associated with poorer prognosis in most cases of solid tumors (Gentles et al., 2015) . Technically, TAM consists of a heterogeneous mixture of immature myeloid cells and are mainly divided into M1-( Figure 5A ) and M2-like ( Figure 5B ) phenotypes, where the latter one is predominant in tumors (Fujimura et al., 2016) . In humans, M2 can be further classified into M2a, M2b, and M2c, which are differentiated from M0 by IL-4/IL-13, immune complexes, IL-1β or LPS, and IL-10/transforming growth factor (TGF)-β/glucocorticoids, respectively (Mantovani et al., 2009; Chistiakov et al., 2015) . Generally, in the TME, a high level of M1-TAM usually indicates a better outcome for its anti-tumor effect, though, sometimes, it can also trigger tumorigenesis via chronic inflammation (Qian and Pollard, 2010) . Normally, it is capable of antigen presentation and high expression of pro-inflammatory cytokines (e.g., IL-1, IL-6, IL-12, IL-18, IL-23, and high levels of IL-1 receptor type I (IL-1RI)) (Santoni et al., 2013; Chavez-Galan et al., 2015) . Regarding chemokines, CXCL9 and CXCL10 can be produced for the recruitment of Th1 T cells, which allows the achievement of subsequent killing of tumor (Verreck et al., 2004; Santoni et al., 2013; van Dalen et al., 2019 ) ( Figure 5C ). These kinds of TAMs also exhibit potent phagocytosis and cytotoxicity toward tumor cells by secreting NO, reactive oxygen intermediates (ROI), and TNF-α (Mantovani et al., 2005) (Figure 5D ). However, M1 cells can be polarized into the M2 type via Th2 cell-derived IL-4, IL-10, and IL-13 (van Dalen et al., 2019) ( Figure 5E ). M2-TAM tends to dismiss the capability of antigen presentation and tends to secrete immunosuppressive molecules, such as IL-4, IL-10, TGF-β ( Figure 5F ), adrenomedullin, vascular endothelial growth factors (VEGFs) ( Figure 5G ) and so forth to help complete angiogenesis, debris scavenging, tissue re- Figure 5 Major types of tumor-associated macrophages (TAM) and the network of interactions between the macrophage, T cell, tumor cell, and Treg. TAMs are divided into two main types: M1 (A) and M2 (B). The M1 TAM is pro-inflammatory while the M2 TAM is anti-inflammatory. The M1 TAM is capable of exerting indirect cytotoxicity via the secretion of cytokines such as IL-1, IL-6, IL-12, and IL-18 or chemokines such as CXCL9 and CXCL10 to stimulate the immune response of Th1 cells (C). Moreover, it can present tumor antigens via phagocytosis and exert direct tumor-cell cytotoxicity via NO and ROI (D). Conversely, M2 cells exert an immunosuppressive trait via the inhibition of the immune response of effector T cells using immunosuppressive molecules: e.g., IL-4, IL-10, and TGF-β (F). Through the excretion of adrenomedullin and VEGF, M2 TAMs support tumor angiogenesis and debris scavenging (G). Furthermore, M2 cells can also induce nTreg functions via the production of cytokines including IL-4, IL-10, and TGF-β or chemokines such as CCL17, CCL22, and CCR4 (H). Importantly, M1 and M2 can transform into one another (polarization) in certain circumstances by the presence of different cytokine patterns in the tumor microenvironment (E, I). IFN-γ, interferon-γ; LPS, lipopolysaccharide; NO, nitric oxide; nTreg, naturally occurring Treg cell; ROI, reactive oxygen intermediate; TGF-β (transforming growth factor beta); TNF-α, tumor necrosis factor-α; VEGF, vascular endothelial growth factor. modeling, and immune modulation (Wu et al., 2010; Gabrilovich et al., 2012) . Studies have proved that M2 TAM can dampen the proliferation and persistence of CAR-T cells (Ruella et al., 2017) . Moreover, the M2 phenotype can depress tumor immunity by attracting nTreg infiltration via the production of cytokines (IL-10, TGF-β) or chemokines such as CCL17/CCL22 or CCR4 (Columba-Cabezas et al., 2002) ( Figure 5H ). As interferon-γ (IFN-γ, derived from Th1 cells, cytotoxic T cells, and NK cells) and lipopolysaccharide (LPS, from bacteria and other pathogens) exists in the TME, the M2 type will be repolarized into the M1 variant (Chavez-Galan et al., 2015) ( Figure 5I ). To interfere with the protumor activity of TAM, scientists are devoted to discovering targets against them. One of the candidates is colony-stimulating factor 1 receptor (CSF1R), which is especially relevant to M2 TAM . A third-generation anti-CSF1R CAR-T cell was tested for their cytotoxicity on macrophages. The results demonstrated that these CAR-T cells are capable of accurately targeting the macrophage antigens. In addition, they also exhibit potent cytotoxicity, which is promising for CAR-T cells to prevent immunosuppression in the TAM-rich microenvironments.
Immunosuppressive checkpoint ligand/receptor
Immunosuppressive checkpoints are a group of auxiliary molecules which predominantly regulate the adaptive immune response, especially in T cells. These newly found molecules can suppress the adaptive immune response initiated by T, B, and other immune cells (Marcucci et al., 2017; Wieder et al., 2018) . The immune checkpoint consists of two components: the immune checkpoint receptor and immune checkpoint ligand. Both of these can appear on the surface of APCs, T cells, B cells, or tumor cells (Pardoll, 2012) (Figure 6) . Recently, numerous studies have found that solid tumors, including small/non-small cell lung cancer (Garassino et al., 2018) , breast cancer (Kumar et al., 2017) , melanoma (Cervera-Carrascon et al., 2018) , and head and neck squamous cell carcinoma (Chen et al., 2017) express immunosuppressive checkpoints such as PD-1, PD-L1 (B7-H1), PD-L2 (B7-DC) (Shibahara et al., 2018) , and CTLA-4 (Lan et al., 2018) ( Figure 6 ). Among these immunosuppressive checkpoints, the interaction of PD-1 and PD-L1, CTLA-4 and CD80/86 are two pairs of well defined molecules in tumor immunity (Wieder et al., 2018) . PD-1 is homologous to CD28, a co-stimulatory signal on the surface of T cells, and it is a key regulator of the adaptive immune response. PD-1 is expressed on a variety of host immune cells including T cells (primarily), B cells, dendritic cells, and Langerhans cells (Ishida et al., 1992; Pena-Cruz et al., 2010; Thibult et al., 2013; Lim et al., 2016) . PD-1 can be combined with two ligands, PD-L1 and PD-L2, to induce inactivity and apoptosis of CD4 + and CD8 + T cells at the later effector phase while not exerting effects on immunosuppressive T cells such as Tregs (Marmarelis and Aggarwal, 2018; Nishida and Kudo, 2018) . In addition, PD-
Immunosuppressive checkpoint ligand/receptor expressed on T cells, APCs, and tumor cells. PD-1 is mainly expressed by mature effector T cells, and its combination with PD-L1 can downregulate T-cell activation. PD-L1 can be produced by a variety of immune-related cells and tumor cells. Both PD-L1 and PD-L2 can combine with PD-1, resulting in the inactivation and programmed cell death of effector T cells. Additionally, PD-L1 can also target CD80, another essential immunoregulative molecule which is expressed on T cells, APCs, and tumor cells. Similar to PD-1, CD80 can also counteract T-cell function. CTLA-4 is an important immunosuppressive checkpoint which is predominantly expressed on the surface of Tregs and active CD4 + T cells. It can competitively bind with CD80/86 on APCs to prevent the CD80/86 from binding with CD28, an immune-activating molecule, on T cells. APC, antigenpresenting cell; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; MHC, major histocompatibility complex; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; TCR, T cell receptor. L1 can also target CD80 (B7-1), another key immune checkpoint molecule which regulates the immune cell response. Both PD-L1 and CD80 can be expressed on the surface of T cells, tumor cells, or antigen-presenting cells (a bidirectional interaction) (Keir et al., 2008) . In the tumor microenvironment, IFN-γ, TNF-α, IL-4, and IL-10 can upregulate PD-L1 and PD-L2 expression on various types of host immune cells (Kondo et al., 2010; Sanmamed and Chen, 2014; Shibahara et al., 2018; Tang and Zheng, 2018) . Conversely, immunosuppressive IL-10 can be induced by the interaction between PD-1 and PD-L1 (Dong et al., 1999; Trabattoni et al., 2003) . CTLA-4 is a biomarker commonly expressed on the surface of Treg cells as well as activated CD4 + T cells. It exhibits competitive binding to CD80/86 (B7 complex) on APCs, preventing CD80/86 from interacting with co-stimulatory signal CD28 on activated T cells for early T-cell activation (Chan et al., 2014; Marmarelis and Aggarwal, 2018) . CTLA-4 can also deplete CD80/86 on the APCs by trans-endocytosis, thus avoiding these potential targets from being exposed to other T cells with co-stimulatory signals for T-cell activation (Qureshi et al., 2011) . Moreover, CTLA-4 is capable of binding PP2A (protein phosphatase 2) and SHP2 (SH2 domain-containing proteintyrosine phosphatase-2) to control TCR signaling as well as activating phosphatidylinositide3-kinase (PI3K) to decrease IL-2 production, which leads to the decrease of effector function, proliferation, and survival of effector T cells (Seidel et al., 2018; Shi et al., 2018) . In addition to the famous pairs of PD-1/PD-L1 and CTLA-4/B7, T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte-activation gene 3 (LAG-3), as well as T-cell immunoreceptor with Ig and ITIM domains (TIGIT) are three other major immune checkpoints related to immune inhibition and dysfunction in the adaptive immune system (Gardner et al., 2014; Seidel et al., 2018) . Besides immune checkpoints of adaptive immunity, immune checkpoints in the innate immune system should be considered as well. CD47 is highly expressed by tumor cells and it suppresses the phagocytosis of macrophages via binding with signal regulatory protein α (SIRPα) on phagocytes . The interaction between CD47 and SIRPα can also support tumor angiogenesis and damage the anti-tumor function of T cells (Weiskopf, 2017; Tong and Wang, 2018) . The aforementioned TIM-3 can also serve as an immunosuppressive molecule in the innate immunity by its high expression on macrophages after TGF-β induction (Yan et al., 2015) .
Inhibitory metabolic factors
Although solid tumor cells possess heterogeneity in various mutant genes, mutation sites, and gene expression patterns, all types of solid tumors share some common traits including rapid proliferation, infinite growth, local invasion, and remote metastasis (You and Jones, 2012; Punt et al., 2017; Duan, 2018) . Tissue hypoxia is staple during the growth and proliferation of tumor cells, and it is the root of all metabolic changes in the tumor microenvironment. Hypoxia in growing tumors can be categorized into two subtypes: chronic hypoxia, which refers to the constant lack of oxygen supply due to aberrant tumor vasculature, and intermittent hypoxia where the supply from blood vessels are repeatedly turned on and off, leading to fluctuations of oxygen levels in the area surrounding the tumor cells (Thomlinson and Gray, 1955; Brown, 1979) . In chronic hypoxia, the response of tumor cells to hypoxia is basically dependent on heterodimeric hypoxia-inducible transcription factor 1 and 2 (HIF1 and HIF2). Both of these are biomarkers which indicate a worse prognosis for patients suffering from various cancers (Aebersold et al., 2001; Burri et al., 2003; Holmquist-Mengelbier et al., 2006) . Once the tumor cells receive a signal of hypoxia, the genes of HIF are stabilized. This is followed by the binding of HIFαβ to hypoxia response element and activation of the subsequent transcription cascade (Semenza, 2003) . HIF1-α can also induce the upregulation of glucose transporter-1 (GLUT-1) and execute increased glycolysis in tumor cells (Hanahan and Weinberg, 2011) . Lactate is the main product of glycolysis during hypoxia. It weakens the survival and anti-tumor function of T cells and NK cells while downregulating the secretion of TNF by macrophages (Dietl et al., 2010; Brand et al., 2016) . This has been demonstrated by a study in which the inhibition of lactate dehydrogenase remarkably enhances the vulnerability of tumors to adoptive T-cell therapy in vitro and in vivo (Cascone et al., 2018) . To make matters worse, one study suggested that a low-oxygen environment can hinder the expansion, cytokine production, and differentiation as well as induce a higher CD4:CD8 ratio of CAR-T cells, and this is the reason that CAR-T cells are usually disabled in the treatment of patients suffering from solid tumors (Berahovich et al., 2019) . Besides this, hypoxia has an influence on the expression level of immune checkpoint molecules on both T cells and tumor cells. For T cells, low-oxygen levels inhibit the expression of effector T-bet, a T-cell transcription factor, inversely causing an increased expression of CTLA-4 and LAG-3, which results in the disability of CD8 + T cells (Doedens et al., 2013) . Intermittent hypoxia, also known as acute or cyclic hypoxia, has the possibility of strengthening the livelihood of cancer cells, inducing autophagy, preventing ionizing radiation, and selecting for tumor cells which possess stem cell characteristics in different cancers including gastric cancer, lung cancer, pancreatic cancer, melanoma, and neuroblastoma (Liu et al., 2010; Rofstad et al., 2010; Bhaskara et al., 2012; Miao et al., 2014; Zhu et al., 2014) . Some links between hypoxia and immunosuppressive cells have been proposed. A number of published works have shown that HIF-1α, which is induced in hypoxic milieu, can remarkably elevate the production of inducible nitric oxide synthase (iNOS) and arginase (ARG)-1 in MDSC. iNOS can generate NO, which, in turn, can induce T-cell apoptosis as well as block the binding sites of TCR with tumor antigens (Chouaib et al., 2018) . ARG-1 can assist MDSCs to competitively consume and deplete extrinsic L-arginine, which is essential for the development of T cells and TCR expression (Ezernitchi et al., 2006; Rodriguez et al., 2007) . Another supportive point is that miR-210 induced by hypoxia can potentiate MDSC-mediated T-cell suppression, whereas MDSC functions are hindered by miR-210 (Noman et al., 2015) . In addition, HIF1α also enables MDSCs to differentiate into immunosuppressive TAMs (Corzo et al., 2010) .
Tumor antigen loss and antigen heterogeneity
Natural selection is a universal occurrence, and medicine is also not exempted from its effects. When antibiotics are abused, more antibiotic-resistant pathogens will emerge and neutralize the effect of these drugs in treating infections. Likewise, the persisting pressure exerted by CAR-T cells will lead to the survival of a specific group of tumor cells, which employ camouflage by downregulating or even ceasing the expression of their surface antigens Majzner and Mackall, 2018) . This was demonstrated by several studies in both hematological malignancies and solid tumors (Maude et al., 2014; Brown et al., 2015; O'Rourke et al., 2017; Ebert et al., 2018; Maude et al., 2018) . Basically, there are two major pathways of antigen loss: antigen escape and lineage switch (Majzner et al., 2017) . Antigen escape, also known as isoform switch, happens when the tumor cells present another pattern of targeted antigens without being recognized by CAR-T cells. This process is likely to be related to gene mutation in the locus of the antigen (Sotillo et al., 2015; Majzner and Mackall, 2018) . Lineage switch, on the other hand, is an alternate route of differentiation of tumor cells. The main cause is uncertain, but there are some possible causes including survival clones in distinct phenotypes, progenitors capable of two-way differentiation, cell reprogramming, or de-differentiation Majzner et al., 2017) . A latest theory is put forward: trogocytosis. Using animal models, scientists found that CARs can cause active, reversible antigen loss through the "snatching" of tumor antigens by T cells. As a result, specific tumor antigen density is reduced, whereas the CAR-T cells become more susceptible to other fraternal CAR-T cells because the tumor antigen is now expressed on the cell surface membrane of T cells, resulting in immune disability and T-cell exhaustion (Hamieh et al., 2019) . In the case of heterogeneity, there are two major understandings defining it. One is the change in the expression level and the dis-tribution of neoantigens of the tumor cell surface, and the other is the diversity of tumor biomarkers . The former one has been previously mentioned, where there is an overlap with antigen loss Majzner and Mackall, 2018) . The latter one is a typical feature of solid tumors Tirosh et al., 2016; Ye et al., 2018) .
In the process of carcinogenesis, initial tumor clones come into contact with stromal and immune cells and convert them into premalignant cells (Sabaawy, 2013) . With subsequent changes in the genotype and phenotype, the premalignant cells will differentiate into various tumor clones, presenting diverse surface markers or intracellular neoantigens (Sabaawy, 2013; Ye et al., 2018) . The symbiosis between the malignant and non-malignant cells therefore leads to tumorigenesis . Thus, the network of tumor growth and development in different sites confuses the recognition of CAR-T cell to target and eliminate the "enemy" (Jimenez-Sanchez et al., 2017; Zheng et al., 2017) . In summary, there is a network in which all related cells or cytokines exert their effect on traditional effector T cells. Likewise, CAR-T cells can also be adversely affected by these negative factors because their genome is highly homogeneous to CD4 + or CD8 + T cells. Tregs can directly crash CAR-T cells by granzymeB, perforins, and FasL, or indirectly inhibit the function of CAR-T cells via the depletion of IL-2 or the secretion of IL-10 or TGF-β. The immunosuppressive capacity of Tregs can be strengthened by IL-10 and TGF-β from M2-type TAMs. It is possible for TGF-β to induce CD4 + CD25 effector T cells, converting them into CD4 + CD25 + Tregs. MDSCs suppress CAR-T cells by IL-10, enzymes, ROS, or being stimulated by macrophages. MDSCs can also inhibit CAR-T function by communicating with tumor cells via IL-10, NO, IL-6, etc. TAM is a two-edged sword to CAR-T. The T-cell-beneficial M1 type can boost tumor antigenicity by presenting antigens to Th1 cells, which can activate CAR-T cell function. Alternatively, it can directly swallow and eliminate tumor cells or kill them via cytotoxic substances such as NO, ROI, and TNF-α. M2type TAMs, on the other hand, inhibit CAR-T cell function via chemokines, assisting tumor cell growth and proliferation, or activating Th2 and nTreg to inhibit CAR-T cell functions. Besides the surroundings of tumor cells, the tumor cells themselves can suppress CAR-T cell function by ligation of their immunosuppressive checkpoint ligands with their corresponding receptors expressed on CAR-T cells such as PD-1, CD80, CTLA-4, and so forth. Additionally, cancer cells can expedite Treg differentiation to weaken CAR-T anti-tumor function. Besides this, they can hide themselves via discarding their representative antigens or ceaselessly changing their antigens, confusing the specific attacks of CAR-T cells. Hence, solid tumor tissue and their surrounding immunosuppressive network are obstacles for CAR-T cell therapy.
Up-to-date technology of CAR-T cells to overcome the barriers in treating solid tumors
To surmount all the barriers mentioned above, brand-new adoptive immune cells have been designed and updated over the years. Nevertheless, mounting evidence suggests that the immunosuppressive tumor microenvironment will result in poor expansion and persistence of CAR-T cells in the human body (John et al., 2013; Cherkassky et al., 2016; Avanzi et al., 2018) . On the basis of the previous three generations of CARs, the fourth generation of CAR-T cells, also designated T cells redirected for universal cytokine-mediated killing (TRUCKs) or "armored T cells," is created by genetically adding an inducible cytokine-producing cassette (e.g., . Cytokines can be produced and secreted right after TRUCK cells specifically combine with antigens on tumor cells (Van Schandevyl and Kerre, 2018) ( Figure 7) . The cytokines can activate CAR-T cells, TILs, and other innate immune cells such as anti-tumor macrophages and NK cells (Van Schandevyl and Kerre, 2018) . The cassettes include proteins such as cytokines (IL-12, IL-15, IL-18, IL-21) (Chmielewski and Abken, 2012; Yeku and Brentjens, 2016; Krenciute et al., 2017; Yeku et al., 2017; Avanzi et al., 2018) and ligands of receptors on other immune cells or tumor cells (CD40L) (Yeku and Brentjens, 2016) . Some bench studies demonstrated that CAR-T cells equipped with cytokines can reverse the immunosuppressive tumor microenvironment not only by enhancing their own lifespan and expansion, but also by activating the immune effector cells and promoting their growth and proliferation (Kerkar et al., 2011; Koneru et al., 2015; Yeku and Brentjens, 2016; Avanzi et al., 2018) . In addition, cytokines secreted by T cells can reduce, eliminate, or even reverse the function of immunosuppressive cells such as Tregs or TAMs (Pegram et al., 2012) . The precise attacks launched by armored T cells can circumvent the severe treatment-related toxicity and mortality caused by previous systemic injections of large doses of IL-12 (Leonard et al., 1997; Lacy et al., 2009) . Besides this, T cells armored with other molecules such as CD40L or 4-1BBL can augment the vulnerability of tumor cells to immune attacks (Curran et al., 2015) and stimulate more pro-inflammatory cytokines which are beneficial for T-cell activation, persistence, and expansion (Zhao et al., 2015) . Facing immunosuppressive environments filled with various kinds of anti-inflammatory cytokines or other common inhibitory molecules (e.g., IL-4, IL-10, TGF-β, and PD-1), scientists have engineered T cells with mutated genes capable of expressing invalid receptors of these cytokines or even enabling T cells to swap immunosuppressive signals to proinflammatory ones so that the adoptive immune cells can break through this immunosuppressive barrier secreted by tumor cells Leen et al., 2014; Cherkassky et al., 2016; Kloss et al., 2018) . One study even forces the T cells to express and secrete PD-1/PD-L1-blocking monoclonal antibodies both in an autocrine and paracrine manner to enhance T cell effects (Suarez et al., 2016; Rafiq et al., 2018) . To overcome the difficulty of CAR-T migration to tumor sites, furnishing CAR-T cells with genes of CCR, CXCR, or other receptors to chemokines secreted by solid tumors is another option to improve the homing of T cells and the capability of migration and achieving access to tumor cells (Craddock et al., 2010; Moon et al., 2011; Knochelmann et al., 2018) .
To avoid ineffective treatment due to antigen loss, bispe-
Figure 7
The fourth generation of CAR-T cells and its function in tumor immunity. Based on the previous three generations, the fourth generation of CAR-T cells, also known as "T cells redirected for universal cytokine-mediated killing (TRUCKs)" or "armored T cells," introduces a gene of inducible cytokine cassette (e.g., IL-12) to the T-cell genome. Cytokines can be produced and secreted as soon as TRUCK cells specifically combine with antigens on tumor cells. The cytokines can stimulate CAR-T cells, TILs, and other innate immune cells such as macrophages. Mφ, macrophage; TIL, tumor-infiltrating lymphocyte; TRUCKs, T cells redirected for universal cytokine-mediated killing.
cific CAR-T cells can launch a double attack on the evasive tumor cells . Bispecific CAR-T comprises two patterns. One is a CAR monomer where two different scFvs exist "hand-in-hand" on a single cell (dual antigen target tandem CAR therapy, TanCAR) or when two separate CAR monomers with different scFvs exist on one cell (dual signaling CAR therapy) ( Figure 8A ). The other one is the formation of T-cell pools with different types of CARs infused sequentially or simultaneously (dual antigen target CAR therapy) Zhao et al., 2018) . However, instability of the scFv sections persists because of the shortage of structural support by the IgG constant regions or even the presence of CAR monomers on a single cell, causing oligomerization with each other, clustering, and ligand-independent tonic signaling (a kind of signaling which originates internally rather than being dependent on external antigens) (Ajina and Maher, 2018) . The selection of a proper coexisting epitope is another important topic to be discussed (Sadelain, 2016) . Due to the limitations and difficulties in using CAR-T cells, combination therapy is another alternative in clinical oncology Lamers et al., 2016) . Globally, clinical trials have been assessing the results of the combination of CAR-T cells with other treatments, including chemotherapy, other types of immunotherapy, and other treatments . In chemotherapy, the drugs can mitigate tumor volume (Alizadeh et al., 2014; Sistigu et al., 2014) , making tumor cells more vulnerable to the attack of the CTLs (Ramakrishnan et al., 2012; Parente-Pereira et al., 2013) , thereby enhancing the exposure of tumor antigens and aiding the antigen presentation by dendritic cells and TILs (Senovilla et al., 2012; Ma et al., 2013; Garg et al., 2015) . Moreover, certain chemotherapeutic agents (i.e., cyclophosphamide, docetaxel, doxorubicin, fluorouracil, and gemcitabine) can disable the function of immunosuppressive cells like Tregs and MDSCs without disrupting the effects of adoptive T cells when the drugs are given in a low dose (Traverso et al., 2012; Alizadeh et al., 2014) . Finally, the assistance of CAR-T cell therapy with checkpoint-inhibitor blockades (anti-CTLA-4, anti-PD-1, and anti-PD-L1) is highlighted in recent years, and some agents such as anti-CTLA-4 antibodies (ipilimumab and tremelimumab) and anti-PD-1 antibodies (nivolumab, pembrolizumab, and pidilizumab) have been approved by the US Food and Drug Administration (John et al., 2013; Xu et al., 2018) . These agents, especially anti-PD-1, can specifically prevent immunosuppression and exhaustion of T cells by tumor cells and extend the persistence of effector T cells in vivo (John et al., 2013; Burga et al., 2015) . In addition to antibodies, some studies have found that some microRNAs or even lncRNAs are influential on or related to immune processes and carcinogenesis, and there is no exception to CAR-T cell treatment (Xu et al., 2019; . For instance, using an RNA interference technique including microRNA (miRNA) is another option for combination therapy, in that miRNA can inhibit some inhibitory molecules in tumor cells and indirectly enhance CAR-T cell cytotoxicity Ji et al., 2019) .
In contrast to the "addition protocol," namely to add more elements to CAR-T cells or to apply other agents to optimize its function, the "subtraction protocol" has been used to remove some unnecessary or harmful elements from the T cells, offering another direction to further enhance the antitumor effect. The key element of this subtraction protocol lies in the gene-editing technique. Among these techniques, the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system is of great importance. The gene of PD-1 can be edited from the exhausted CAR-T cells using the CRISPR/Cas9 system, where some clinical trials utilizing this technology are currently underway (Menger et al., 2016; Su et al., 2016; Rupp et al., 2017; Hu et al., 2019) (https://clinicaltrials.gov/ct2/show/NCT03399448? term=NCT03399448&draw=2&rank=1). However, some scientists have suggested that the intervention of PD-1 genes in T cells will adversely affect their survival and will conversely promote further exhaustion of naïve T cells (Odorizzi et al., 2015) . Besides the examples mentioned above, knockout of diacylglycerol kinase (DGK), a TCR-inhibitory checkpoint, is another option to add CAR-T cell resistance to immunosuppressive molecules such as TGF-β and prostaglandin E2 (PGE2) by strengthening the TCR signaling (Riese et al., 2013; Jung et al., 2018) . Similarly, deletion of other "enemy molecules" of the T cells via the CRISPR/Cas9 system including LAG-3 and FASL (indicators of differentiation or apoptosis of T cells) (Eyquem et al., 2017) is also a promising approach to enhance the persistence and antitumor effects of CAR-T cells (Peter et al., 2015; Klebanoff et al., 2016) . Besides this, RNA interference is another wellknown technology in compliance with the "subtraction protocol," and it has made a breakthrough especially in the target therapy of tumors (Saw and Song, 2019) . Some researchers have been devoted to delivering CAR-T cells with small-interfering RNAs (siRNAs) to downregulate PD-1 and CTLA-4. Through electroporation, this type of CAR-T acquired more cytotoxicity and successfully avoided activation-induced upregulation of these two immunosuppressive checkpoint receptors (Simon et al., 2018) .
Conclusion
CAR-T cell therapy has made quantum leaps in recent years, especially in the treatment of hematological malignancies. Through this regimen, patients with acute lymphoblastic leukemia report a CR rate of 90% and sustained remissions of up to two years (Maude et al., 2014) . Nevertheless, multiple challenges remain in the treatment of solid tumors. It seems that discovering a novel neoantigen is still a main goal for researchers, and this represents the principle of precision medicine. However, the contribution of innate immunity toward immunotherapy should not be overlooked. In the TME, we can readily identify that almost half of all the factors impacting the function of T cells are related to the innate immune system. Also, the high heterogeneity caused by gene mutation and rapid antigen escape is overtaking our speed of searching for a novel antigen. In addition, when we reconstruct CAR-T cells, we should not neglect the importance of the TCR. One study has reported the creation of a receptor that is TCR-dependent but MHC-independent, designated T cell antigen coupler (TAC) (Helsen et al., 2018) . It has three domains: an antigen-binding domain, a TCR-recruitment domain, and a co-receptor domain (hinge, transmembrane, and cytosolic regions). This TAC not only demonstrated successful avoidance of CAR toxicity (Abate-Daga and Davila, 2016) and the exertion of a milder T-cell response, but it also exhibited stronger infiltration into tumors and a more powerful anti-tumor activity (Helsen et al., 2018) . This study reminds us that we can potentially achieve more with the reconstruction of CAR-T cells, surpassing the invention of "tri-/quadra-specific" CAR-T cells by the addition of more monoclonal antibodies. A possible future for CAR-T cell development is to combine its highly specific traits (monoclonal antibody) with more elements of nonspecific ones (such as TRUCKs, i.e., to recruit other kinds of immune cells into the battlefield). Of course, this progress is currently based on the level of gene-editing for the time being. If possible, we strive to work on the genome level, fusing innate and adaptive immunity into T cells. For example, we can empower CAR-T cells with the ability of antigen presentation or phagocytosis, or even to produce and secrete antibodies instead of requiring direct contact with cancer cells, which can avoid the problems of homing and infiltration. Above all, CAR-T cells are not just soldiers, they can be leaders to stimulate, activate, and preside over the entire immune system. This represents our ultimate goal in tumor immunity: to win the war against the tumor microenvironment.
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